Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Mesoblast Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Apr 2016 Reuters Investment Profile 12 $20.00

Mesoblast Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

30 Apr 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Mesoblast Ltd (MSB-AU)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

26 May 2016 Thomson Reuters Stock Report 11 $25.00

Mesoblast Limited - Mesoblast Receives $6.2 Million from Australian Government for Research and Development Activities

20 May 2016 irasia.com 1 $12.00

Wright Investors Service Comprehensive Report for Mesoblast Ltd

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

18 May 2016 Wright Reports 55 $75.00

Mesoblast Limited (ASX- MSB; NASDAQ- MESO)

Mesoblast Limited is a world leader in the development of biologic products for the broad field of regenerative medicine. Th...

17 May 2016 Acquisdata 16 $15.00

Mesoblast Limited (MSB) - Financial Analysis Review

Mesoblast Limited (MSB) - Financial Analysis Review Summary Mesoblast Limited (Mesoblast) is a regenerative medicine company ...

16 May 2016 GlobalData 47 $300.00

MESOBLAST - CHF PHASE III CLEARS INTERIM SAGETY ANALYSIS

In its Q3 FY16 results presentation Mesoblast revealed the Phase III trial of Revascor in CHF cleared its first interim safet...

11 May 2016 Edison Investment Research 3 $10.00

Mesoblast Limited - Form 6-K - Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 - Filed in the Month of May 2016 for the Period Ended March 31, 2016

10 May 2016 irasia.com 110 $1,265.00

Mesoblast Limited - Financial Results for the Nine Months and Third Quarter Ended 31 March 2016

10 May 2016 irasia.com 24 $276.00